Bristol-Myers Squibb’s study met its co-primary endpoint of overall survival with Opdivo® (nivolumab) plus low dose Yervoy® (ipilimumab) vs. chemotherapy in first-line Non-Small Cell Lung Cancer patients whose tumors expressed PD-L1 ≥1%. This is the third tumor type in which Opdivo plus Yervoy demonstrates overall survival benefit in a Phase 3 Trial. Learn more HERE
Read More
AstraZeneca’s trastuzumab deruxtecan was granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer.Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer who have limited treatment options today. Learn more at:
Read More

Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute
Download Here

To increase awareness and management of adverse effects related to trifluridine/tipiracil treatment in metastatic colorectal cancer.

Continue reading Trifluridine / Tipiracil for Treatment of Gastric Cancer

Read More

LOS ANGELES, Calif., Oct. 2, 2019 – Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that the U.S. Food and Drug Administration (FDA) has approved a labeling supplement for NERLYNX® (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer. With the approval of the labeling supplement, the label now includes safety information based on interim results from Puma’s Phase II CONTROL Trial, a study evaluating antidiarrheal prophylaxis or dose escalation in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 or higher diarrhea. Interim data from the trial showed that the addition of prophylactic treatment with loperamide plus budesomide reduced the discontinuation rate due to neratinib-associated diarrhea to 11% versus a discontinuation rate of 18% with loperamide alone. READ MORE

Read More